Evidence map›Paper›PMID 35290593›Full record

ReviewJournal of cardiovascular translational research2022

Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.

Husam M Salah, Subodh Verma, Carlos G Santos-Gallego, Ankeet S Bhatt, Muthiah Vaduganathan, Muhammad Shahzeb Khan, Renato D Lopes, Subhi J Al'Aref, Darren K McGuire, Marat Fudim

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cardiovascular translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Interatrial Shunt Devices.Heart failure clinics · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Husam M SalahDepartment of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Subodh VermaDivision of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.
Carlos G Santos-GallegoDepartment of Cardiology, Mount Sinai School of Medicine, New York, NY, USA.
Ankeet S BhattDivision of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Muthiah VaduganathanDivision of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Muhammad Shahzeb KhanDivision of Cardiology, Department of Medicine, Duke University, 2301 Erwin Road, Durham, NC, USA.
Renato D LopesDuke Clinical Research Institute, Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
Subhi J Al'ArefDivision of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Darren K McGuireDivision of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, TX, USA.
Marat FudimDivision of Cardiology, Department of Medicine, Duke University, 2301 Erwin Road, Durham, NC, USA. marat.fudim@duke.edu.

Funding

TRAINING PROGRAM IN CARDIOVASCULAR RESEARCHT32HL007604 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARK W FEINBERG · 1985 to 2026
$19.0M
Congestion Phenotypes and Splanchnic Nerve Modulation in Chronic Heart FailureK23HL151744 · NHLBI · DUKE UNIVERSITY · PI FUDIM, MARAT · 2021 to 2022
$376k
NHLBI NIH HHS K23 HL151744NHLBI NIH HHS T32 HL007604
6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction (only empagliflozin and dapagliflozin have been investigated in this group so far), and chronic kidney disease. Prevention and reversal of adverse cardiac remodeling is one of the mechanisms by which SGLT2 inhibitors may exert cardiovascular benefits, especially heart failure-related outcomes. Cardiac remodeling encompasses molecular, cellular, and interstitial changes that result in favorable changes in the mass, geometry, size, and function of the heart. The pathophysiological mechanisms of adverse cardiac remodeling are related to increased apoptosis and necrosis, decreased autophagy, impairments of myocardial oxygen supply and demand, and altered energy metabolism. Herein, the accumulating evidence from animal and human studies is reviewed investigating the effects of SGLT2 inhibitors on these mechanisms of cardiac remodeling.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsAnimalsGlucoseHumansSodiumStroke VolumeVentricular RemodelingGlucoseSodiumSodium-Glucose Transporter 2 InhibitorsCardiac remodelingHeart failureHFpEFHFrEFMechanismsSGLT2iSGLT2 inhibitors

Identifiers

PMID35290593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.